NEW YORK (GenomeWeb) – Bio-Techne said today that its fiscal 2019 second quarter revenues rose 13 percent year over year.

For the three months ended Dec. 31, 2018, the firm said revenues rose to $174.5 million from $154.2 million, beating the analysts' average estimate of $170.2 million.

In Q2, the firm's Diagnostics and Genomics revenues were $39.3 million, up 6 percent year over year from $37.1 million. Bio-Techne's Protein Sciences revenues were $135.5 million, up 16 percent from $117.1 million in the prior-year quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.